Literature DB >> 33755880

Association between preoperative serum TSH and tumor status in patients with papillary thyroid microcarcinoma.

Aihong Mao1,2, Ning An1, Juan Wang1, Yuanyuan Wu1, Tao Wang1,2, Zhuoying Wang3, Haixia Guan4, Jun Wang5.   

Abstract

Thyroid-stimulating hormone (TSH) is a growth factor affecting the initiation or progression of papillary thyroid cancer (PTC). However, the relationship between preoperative serum TSH and papillary thyroid microcarcinoma (PTMC) remains controversial. To investigate the relationship between preoperative serum TSH and tumor status of PTMC, a multicentered retrospective study was performed from January 2014 to December 2016. The cohort of this study consisted of 1997 patients who underwent thyroid surgery. Serum TSH concentrations were measured and PTMC was diagnosed based on the post-operation pathological report. Results showed that the preoperative serum TSH concentration was not related to age and gender but was positively associated with tumor size. Furthermore, higher TSH level was associated with extra-thyroidal extension and lymph node metastasis (LNM). These results indicated that TSH might not be involved in the development of PTMC but may be associated with PTMC progression. Preoperative serum TSH concentration should be considered as risk predictor for tumor progression in patients with PTMC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Papillary Thyroid Microcarcinoma; Thyroid-stimulating Hormone; Tumor progression; Tumor size

Mesh:

Substances:

Year:  2021        PMID: 33755880     DOI: 10.1007/s12020-021-02690-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

Review 4.  [Lectins: properties, functions, and possible applications].

Authors:  Kh Frants
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1980-01

5.  High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.

Authors:  Hye In Kim; Hye Won Jang; Hyeon Seon Ahn; Soohyun Ahn; So Young Park; Young Lyun Oh; Soo Yeon Hahn; Jung Hee Shin; Jung-Han Kim; Jee Soo Kim; Jae Hoon Chung; Tae Hyuk Kim; Sun Wook Kim
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

6.  Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Ozdemir; Cevdet Aydın; Nagihan Bestepe; Serap Ulusoy; Nuran Sungu; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2018-01-27       Impact factor: 3.633

7.  Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

Authors:  Megan Rist Haymart; Daniel John Repplinger; Glen E Leverson; Diane F Elson; Rebecca S Sippel; Juan Carlos Jaume; Herbert Chen
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

8.  Changing trends in thyroid cancer incidence in Canada: A histologic examination, 1992 to 2016.

Authors:  Larry F Ellison; Tracey Bushnik
Journal:  Health Rep       Date:  2020-01-15       Impact factor: 4.796

9.  Thyroid Hormones, Autoantibodies, Ultrasonography, and Clinical Parameters for Predicting Thyroid Cancer.

Authors:  Lin-Zheng He; Tian-Shu Zeng; Lin Pu; Shi-Xiu Pan; Wen-Fang Xia; Lu-Lu Chen
Journal:  Int J Endocrinol       Date:  2016-05-19       Impact factor: 3.257

10.  Association of Preoperative Serum Thyroid-stimulating Hormone Levels with Thyroid Cancer in Patients with Nodular Thyroid Disease.

Authors:  Muhammad Aleem Khan; Nadeem Malik; Kamran Hakeem Khan; Muhammad Faheem Shahzad
Journal:  World J Nucl Med       Date:  2017 Jul-Sep
View more
  3 in total

1.  The optimal extent of lymph node dissection in N1b papillary thyroid microcarcinoma based on clinicopathological factors and preoperative ultrasonography.

Authors:  Xiao-Nan Liu; Yuan-Sheng Duan; Kai Yue; Yan-Sheng Wu; Wen-Chao Zhang; Xu-Dong Wang
Journal:  Gland Surg       Date:  2022-06

Review 2.  Fish and the Thyroid: A Janus Bifrons Relationship Caused by Pollutants and the Omega-3 Polyunsaturated Fatty Acids.

Authors:  Salvatore Benvenga; Fausto Famà; Laura Giovanna Perdichizzi; Alessandro Antonelli; Gabriela Brenta; Francesco Vermiglio; Mariacarla Moleti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

3.  The Effect of ThyroidߚStimulating Hormone on Stage of Differentiated Thyroid Carcinoma.

Authors:  Laya Soleimanisardoo; Mohsen Rouhani; Fatemeh Soleymani Sardoo; Mohammad Hossein Gozashti
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.